{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 921f56a3-d46e-4dfa-a6d9-a74701653c5b --><h2>Metronidazole</h2><!-- end field 921f56a3-d46e-4dfa-a6d9-a74701653c5b -->","summary":"","htmlStringContent":"<!-- begin item d4add0bb-911c-43a0-924d-a74701653d66 --><!-- end item d4add0bb-911c-43a0-924d-a74701653d66 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1868a183-083f-52cd-970c-209c3c71f956","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f46fca24-dd07-4460-a170-a74a00c39d15 --><h3>Contraindications and cautions</h3><!-- end field f46fca24-dd07-4460-a170-a74a00c39d15 -->","summary":"","htmlStringContent":"<!-- begin item 91c22d79-df24-471c-b123-a74a00c39cdf --><!-- begin field 99de0ded-ab05-4fb0-ac69-a74a00c39d15 --><ul><li><strong>Do not prescribe metronidazole to a person with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole.</li></ul></li><li><strong>Prescribe metronidazole with caution </strong><strong>to people with:</strong><ul><li>Active or chronic severe peripheral and central nervous system disease, as there is a risk of neurological aggravation.</li><li>Severe liver disease or hepatic encephalopathy, due to substantial impairment of metronidazole clearance, which may contribute to symptoms of encephalopathy. Prescribe one-third of the daily dosage once daily.</li><li>Alcohol dependency — there may be a disulfiram-like reaction if taken with alcohol.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field 99de0ded-ab05-4fb0-ac69-a74a00c39d15 --><!-- end item 91c22d79-df24-471c-b123-a74a00c39cdf -->","subChapters":[]},{"id":"9f7de0af-0312-5ff2-853d-f420a992620a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b8f5c40c-352f-4595-9f39-a74a0112dd49 --><h3>Adverse effects</h3><!-- end field b8f5c40c-352f-4595-9f39-a74a0112dd49 -->","summary":"","htmlStringContent":"<!-- begin item 84116972-525b-4d69-aaad-a74a0112dcd4 --><!-- begin field 8b5d3653-d69e-49c1-944b-a74a0112dd49 --><p><strong>Adverse effects of metronidazole include:</strong><strong> </strong> </p><ul><li>Gastrointestinal disturbances including nausea and vomiting, anorexia, and very rarely hepatitis, jaundice, or pancreatitis.</li><li>Taste disturbances, furred tongue, oral mucositis.</li><li>Headache, ataxia.</li><li>Thrombocytopenia, pancytopenia. </li><li>Myalgia, arthralgia.</li><li>Darkening of urine.</li><li>Rash, pruritus, and erythema multiforme.</li><li>Drowsiness, dizziness, confusion, hallucinations, convulsions, or transient visual disorders. Advise the person not to drive or operate machinery if these symptoms occur.</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field 8b5d3653-d69e-49c1-944b-a74a0112dd49 --><!-- end item 84116972-525b-4d69-aaad-a74a0112dcd4 -->","subChapters":[]},{"id":"ea01364b-d8c2-50da-8826-536ab31b9ab7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 583e0a17-0603-455f-b6b3-a74a0112eafd --><h3>Drug interactions</h3><!-- end field 583e0a17-0603-455f-b6b3-a74a0112eafd -->","summary":"","htmlStringContent":"<!-- begin item 83797d52-e502-4c7f-a3a5-a74a0112eab8 --><!-- begin field b23fa9ea-bafa-4f4b-8285-a74a0112eafd --><p><strong>Drug interactions associated with metronidazole include: </strong></p><ul><li><strong>Alcohol </strong>— some people taking metronidazole experience a disulfiram-like reaction with alcohol.<ul><li>Warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst on metronidazole and for at least 48 hours afterwards. </li></ul></li><li><strong>Anticoagulants </strong>— the anticoagulant effects of warfarin can be markedly increased by metronidazole. <ul><li>Monitor the international normalized ratio (INR) and adjust the warfarin dose accordingly. </li></ul></li><li><strong>Ciclosporin </strong>— if co-administration of metronidazole and ciclosporin is necessary, serum ciclosporin levels and serum creatinine should be closely monitored.</li><li><strong>Cimetidine </strong>— metabolism of metronidazole inhibited by cimetidine, resulting in an increased plasma concentration.</li><li><strong>Lithium </strong>— seek specialist advice regarding the use of metronidazole with lithium, as metronidazole increases the risk of lithium toxicity. Lithium dose reduction may be required due to the risk of renal damage with concurrent use. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored if metronidazole and lithium are used simultaneously.</li><li><strong>Phenytoin </strong>— metronidazole possibly inhibits the metabolism of phenytoin, leading to increased plasma concentrations.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field b23fa9ea-bafa-4f4b-8285-a74a0112eafd --><!-- end item 83797d52-e502-4c7f-a3a5-a74a0112eab8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}